Transitional cell carcinoma (TCC) is the most common type of bladder cancer. Here we sequenced the exomes of nine individuals with TCC and screened all the somatically mutated genes in a prevalence set of 88 additional individuals with TCC with different tumor stages and grades. In our study, we discovered a variety of genes previously unknown to be mutated in TCC. Notably, we identified genetic aberrations of the chromatin remodeling genes (UTX, MLL-MLL3, CREBBP-EP300, NCOR1, ARID1A and CHD6) in 59% of our 97 subjects with TCC. Of these genes, we showed UTX to be altered substantially more frequently in tumors of low stages and grades, highlighting its potential role in the classification and diagnosis of bladder cancer. Our results provide an overview of the genetic basis of TCC and suggest that aberration of chromatin regulation might be a hallmark of bladder cancer.
in FGFR3 and the Ras gene family, and MI-TCCs usually have defects in TP53 and RB1 in high-grade tumors. These discoveries provided important insights into potential diagnoses and therapeutic applications, yet no comprehensive analysis of this cancer has been performed. In this study, we aimed to screen TCC systematically to identify other previously unidentified bladder-cancer-associated genes.
We performed whole-exome sequencing of the genomic DNA from tissue samples from nine individuals with MI-TCC (stage ≥ T2; Supplementary Table 1) and their matched peripheral blood samples. In this stage, called here the 'discovery screen' , we primarily focused on MI-TCC because of its poor prognosis and survival. We generated sequencing reads with an Illumina GAII platform (Illumina, Inc.) and aligned them to the reference human genome (hg18) using MAQ 3 and BWA 4 software (Online Methods). On average, we sequenced the 34-Mb targeted exome regions of each sample to a mean depth of 100× or greater ( Supplementary Fig. 1a and Supplementary Table 2 ). Over 95% of the target regions were covered sufficiently for confident variant calling (defined as ≥10×; Supplementary Fig. 1b) .
To identify somatic mutations, we compared the sequencing data generated from the tumor-normal sample pairs of each subject (Online Methods). To eliminate any previously described germline variants, we cross-referenced potential somatic mutations against the dbSNP130 and SNP datasets of Han Chinese in Beijing (CHB) and Japanese in Toyko (JPT) from the three pilot studies in the 1000 Genomes Project. Based on these criteria, we identified 465 predicted somatic mutations, including 105 synonymous mutations, Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder l e t t e r s 284 missense mutations, 45 nonsense mutations, 2 splice-site changes and 29 small coding insertions or deletions (indels) (Supplementary Table 3 ). Of the 221 predicted somatic substitutions and 12 indels that we randomly selected for validation, we confirmed 200 (90.5%) and 8 (66.7%) by genotyping and Sanger sequencing, respectively (Online Methods). The mutation spectrum in the nine TCC samples was dominated by C:G>T:A transitions (Supplementary Fig. 2 ), as has been reported in several other human cancers 5 .
To further evaluate the mutation prevalence of 328 genes that had at least one non-silent somatic mutation in the discovery screen, we determined the coding sequences of these genes in a prevalence screen of 88 additional individuals with TCC (Supplementary Table 1 ). We included both individuals with MI-TCC (51 individuals) and NMI-TCC (37 individuals) to investigate whether there are genes that may be preferentially mutated in any subgroups of affected individuals. In addition, in this stage, we also screened two other well-known bladder cancer genes (FGFR3 and RB1) 2 without somatic mutation in the discovery stage. In brief, we enriched the targeted exonic sequences of matched normal and tumor DNAs from the 88 untreated subjects followed by Illumina-based resequencing (Online Methods). Overall, we achieved a mean coverage depth of ~80× for all the samples sequenced, with at least ~85% of the targeted bases being sufficiently covered (≥10×; Supplementary Table 4) . We determined somatic mutations using the same method as used in the discovery screen, and we selected all the non-silent mutations for verification by genotyping or Sanger sequencing (Supplementary Table 5 ).
We combined mutations obtained from the discovery and validation screens to prioritize the significantly mutated genes that are likely to be implicated in TCC tumorigenesis. We considered a gene to be a potential significantly mutated gene if the gene harbor confirmed non-silent mutations in at least two tumors and if its non-silent mutation rate was significantly higher (P < 0.05) than the background (Supplementary Table 6 and Online Methods). In total, we identified 54 significantly mutated genes in our dataset (Supplementary Table 7 ). Five of the significantly mutated genes have previously wellestablished roles in TCC ( and CREBBP-EP300 (c) using the following symbols: red stars, nonsense mutations; bullets, missense mutations; red triangles, frame-shift indels; green triangles, in-frame indels; and diamond, mutations at splice sites. Domains and motifs in each encoded protein product, as well as the key region responsible for the histone acetyltransferase activity of CREBBP, are also indicated. TPR, tetratricopeptide repeat; JmjC, transcription factor jumonji/aspartyl beta-hydroxylase; ARID, AT-rich interactive domain; LXXLL, C-terminal leucine-rich LXXLL motif; CH1, CH2 and CH3, cysteine-histidine-rich domains; KIX, CREB-binding domain; Bromo, bromodomain. l e t t e r s with no previously well-defined roles in TCCs, and 33% (16 out of 49) of these genes were frequently mutated genes that showed mutations in more than 5% of TCCs ( Table 1) .
Most notably, we detected frequent non-silent mutations in eight genes that are involved in the chromatin remodeling process ( Table 1) . Of these genes, the most frequently altered were the histone demethylase gene (HDMT) UTX (mutated in 21% of TCCs), two histone acetyltransferase (HAT) genes, CREBBP and EP300, and the SWI/SNF-related chromatin remodeling gene ARID1A (with all these genes being mutated in 13% of TCCs). We also detected aberration of each of the remaining four genes in more than 5% of TCCs, including the histone methyltransferase (HMT) genes MLL and MLL3 and two other chromatin remodeling genes, NCOR1 (encoding a constitutive subunit for the N-coR-HDAC3 complex that possesses histone deacetylation (HDAT) activity 10 ) and CHD6 (encoding a component of SNF2/RAD54 helicase family that remodels chromatin to allow cell-type-specific gene expression 11 ).
Genetic alterations of the genes involved in the chromatin remodeling process were also reported in various other tumors in recent studies. Inactivating mutations in UTX were observed in multiple types of cancers 12 ; frequent mutations of ARID1A were identified in ovarian clear cell carcinoma 13 ; and truncating mutations in the HMT gene SETD2, the HDMT gene JARID1C and another member of the SNF/ SWI complex, PBRM1, were identified in renal cell carcinoma 14, 15 . Aberrations of the chromatin remodeling genes may directly lead to the misregulation of multiple downstream effector genes, consequently promoting the tumorigenesis process 16 . Nevertheless, to our knowledge, except for UTX, which showed alterations in 2 of 14 TCC cell lines 12 , genetic mutations in the genes involved in the chromatin remodeling process have not yet been reported in the primary tumors of TCC. In our study, we that found 57 (59%) subjects harbored nonsilent mutations in chromatin remodeling genes, indicating that disruption of the chromatin remodeling machinery may be one of the main mechanisms that leads to TCC.
In addition to the frequency of mutations in a gene, the nature of the mutations can provide valuable information for classifying the mutated genes as oncogenes (dominant genes) or as tumor suppressors (recessive genes) 17 . Our observations clearly distinguished UTX as a tumor suppressor gene in TCC, as evidenced by its mutation pattern of significant enrichment (16 of 22 mutations; P < 0.001) with truncating mutations. These included 11 nonsense mutations, 4 frameshift indels and 1 splice site change (Fig. 1a) . All but one of these were predicted to truncate the JmjC domain, which is essential for the demethylase activity of the protein product. We observed the same mutation pattern in ARID1A (Fig. 1b) , in which truncating mutations accounted for 14 (78%) of 18 mutations (P < 0.001) and which generated defective proteins lacking the ARID DNA-binding domain or LXXLL motif. The patterns of mutations in CREBBP and EP300 also suggested their potential tumor suppressing roles in TCC. Recent studies showed that they behave as tumor-suppressor genes in various tumors 18, 19 . In our screen, 73% and 54% of the mutations in these two genes are predicted to disrupt the key HAT functional region in CREBBP and to truncate the CH3 domain that mediates the interactions between p300 and other cellular proteins (for example, p53 and E2F1) 20 in EP300, respectively (Fig. 1c) . Of note, we also identified recurrent truncating mutations in other frequently mutated chromatin remodeling genes (MLL, MLL3 and NCOR1). In previous studies, MLL was shown to be a dominant cancer gene affected by recurrent translocations in leukemias 21 . However, our data, as well as the mutation data recently deposited in COSMIC database (see URLs), supported that MLL and its homolog MLL3 are likely to act recessively in some solid tumors 22, 23 .
The correlations among mutations in the frequently altered genes could provide insights into their functional interactions. We also confirmed in our study the well-known examples of the negative correlations of mutations in TP53 and FGFR3 (ref. 24 ) and of mutations in TP53 and HRAS (ref.
2) (P < 0.05; Supplementary Table 8) , with no sample here having mutations in both TP53 and FGFR3 or HRAS (Fig. 2) . We also found significantly negative correlations between mutations in UTX and the Ras genes (KRAS and HRAS). In addition, we observed positive correlations of mutations between the following pairs of genes: ANK2 and CHD6, LRP2 and ZFHX3, and Sample   UTX  TP53  ARID1A  CREBBP  EP300  RB1  HRAS  FGFR3  LRP2  ERBB3  LAMA4  CHD6  NF1  MLL  ANK2  NCOR1  KRAS  ESPL1  MLL3 ANK3 ZFHX3 Figure 2 Concurrent and mutually exclusive mutations observed in the frequently mutated genes. For each gene (row) indicated, tumors (columns) with or without mutations are labeled in red or blue, respectively. P values for the occurrence of concurrent and mutual exclusive mutations in two genes across tumors are provided in supplementary table 8. We selected only genes harboring non-silent mutations in at least five subjects for this analysis. CHD6 and LRP2 (all P < 0.05). Notably, we did detect concurrent mutations in multiple genes within the chromatin remodeling process (Fig. 2) , although these correlations were not statistically significant. The eight frequently mutated chromatin remodeling genes can be classified into five subgroups according to their functional specificities: HMT (MLL3 and MLL), HDMT (UTX), HAT (CREBBP and EP300), HDAT (NCOR1) and members of the nucleosomal remodeling complex (ARID1A and CHD6). We found that 16% of TCCs had mutations in at least two of the five subgroups (Fig. 2) . We also observed concurrent mutations within the HAT subgroup between CREBBP and the highly homologous gene EP300. Distinct chromatin remodeling processes are often co-regulated and are functionally dependent 25 . The identification of concurrent genetic alterations in either the same or different subgroups of chromatin remodeling genes probably reflects that they can function synergistically or independently to promote tumorigenesis. We next investigated the relationship between the prevalence of each frequently mutated gene and tumor stage and/or grade. As previously shown 2 , incidence of TP53 mutations increased in TCCs of high stages or grades, whereas the frequency of FGFR3 mutations decreased with increasing tumor stage and grade of TCC (Fig. 3) . Similar to the frequency distribution of FGFR3 mutations across different tumor stages and grades, our analysis indicated that mutations in UTX were likely to be associated with tumors of early developmental stage. The mutation frequency of UTX was significantly associated with tumor grade (P = 0.008), with grade 1 accounting for 35%, grade 2 accounting for 15% and grade 3 accounting for 4% of tumors with mutations in UTX. We also found a negative correlation between mutations in UTX and tumor stage. The incidences of UTX mutations in stage Ta and T1 and in ≥stage T2 tumors were 32% and 13%, respectively (P = 0.04). For the other chromatin remodeling genes (ARID1A, CREBBP and EP300), we found no significant correlations between their mutation frequencies and tumor stage or grade (Fig. 3) .
In summary, our study provides a comprehensive catalog of genetic alterations in TCC, and we discovered 49 new significantly mutated genes associated with TCC. Eight of these are chromatin remodeling genes that harbor frequent mutations in the majority of NMI-TCCs and MI-TCCs. Most of these remodeling genes are likely to act as tumor suppressors and have been reported to play pivotal roles in various tumors other than TCC. These findings further our current understanding of bladder cancer and other human cancers and indicate that genetic alterations and epigenetic deregulations may cooperatively contribute to tumor genesis and progression. Our data can serve as a valuable basis for future studies on TCC and suggest the necessity of epigenomics research in the field of cancer studies.
URLs. COSMIC database, http://www.sanger.ac.uk/perl/genetics/CGP/ cosmic (v52 release); NCBI Consensus Coding Region dataset, http:// www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi; SAMtools, http:// samtools.sourceforge.net/.
MeTHOds
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. All sequencing data from this study are deposited in NCBI Sequence Read Archive under the accession number SRA038181.
Note: Supplementary information is available on the Nature Genetics website. 
